Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DOUG LASS FORSHA

NPI
1285674671
CMS profile
239946
Location
WEST JORDAN, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$12,508.16

80 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $11,136.80 19
AbbVie Inc. $548.55 24
Galderma Laboratories, L.P. $282.75 11
Ortho Dermatologics, a division of Bausch Health US, LLC $179.23 10
Janssen Biotech, Inc. $149.14 5
GENZYME CORPORATION $53.20 3
UCB, Inc. $51.24 2
Lilly USA, LLC $48.26 3
SANOFI-AVENTIS U.S. LLC $30.50 1
Biofrontera Inc. $17.28 1
EPI Health, LLC $11.21 1

Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DOUG LASS FORSHA

NPI 1285674671 · CMS profile ID 239946

WEST JORDAN, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285674671?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DOUG LASS FORSHA, NPI 1285674671, CMS profile ID 239946. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285674671?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). DOUG LASS FORSHA, NPI 1285674671, CMS profile ID 239946. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285674671?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
DOUG LASS FORSHA, NPI 1285674671, CMS profile ID 239946, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1285674671?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

80 matching records · $12,508.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 80 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–80 of 80.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Galderma Laboratories, L.P. $12.7605/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726844319 CMS
PFIZER INC. $13.3005/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743197713 CMS
Janssen Biotech, Inc. $10.4705/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719120917 CMS
Galderma Laboratories, L.P. $16.1804/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726844317 CMS
AbbVie Inc. $18.6604/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721795189 CMS
AbbVie Inc. $19.6104/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721795187 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $14.1204/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737461219 CMS
Galderma Laboratories, L.P. $9.5804/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726844313 CMS
AbbVie Inc. $19.4103/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721795183 CMS
PFIZER INC. $3.6903/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743144953 CMS
PFIZER INC. $4.1503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743145149 CMS
PFIZER INC. $12.8602/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743099383 CMS
UCB, Inc. $23.7602/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749443877 CMS
PFIZER INC. $12.5002/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743090410 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $19.8202/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737461217 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $84.0402/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737461215 CMS
Galderma Laboratories, L.P. $142.9202/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726844309 CMS
AbbVie Inc. $19.0202/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721795175 CMS
AbbVie Inc. $1.7602/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721795179 CMS
Lilly USA, LLC $17.6402/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728410901 CMS
PFIZER INC. $2.6002/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743118957 CMS
PFIZER INC. $4.4602/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743122141 CMS
AbbVie Inc. $20.1701/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721795171 CMS
PFIZER INC. $12.9201/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743073870 CMS
SANOFI-AVENTIS U.S. LLC $30.5001/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744115297 CMS
PFIZER INC. $78.4701/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743089113 CMS
AbbVie Inc. $91.9101/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721795167 CMS
GENZYME CORPORATION $18.6701/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744115305 CMS
Janssen Biotech, Inc. $99.9901/08/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719120915 CMS
PFIZER INC. $4.6201/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743089529 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,955.36 128
PY2020 $12,508.16 80
PY2021 $10,158.22 114
PY2022 $2,336.37 103
PY2023 $21,769.38 183
PY2024 $79,382.79 266
PY2025 $52,804.68 198

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $384,426.60 78
PY2024 Recipient $1,546.92 7
PY2024 Principal investigator $277,588.23 89
PY2023 Principal investigator $324,050.64 53
PY2022 Principal investigator $216,395.21 34
PY2021 Recipient $940.00 1
PY2021 Principal investigator $220,223.79 25
PY2020 Recipient $940.00 1
PY2020 Principal investigator $335,315.52 43
PY2019 Recipient $375.00 1
PY2019 Principal investigator $230,412.59 70

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

78 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,500.00 12/24/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433035
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $200.00 12/24/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433042
Principal investigator 1 Incyte Corporation $1,826.10 12/19/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544869
Principal investigator 1 Incyte Corporation $10,000.00 12/19/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240544876
Principal investigator 1 Incyte Corporation $2,000.00 12/19/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240544886
Principal investigator 1 Incyte Corporation $1,545.30 12/19/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544958
Principal investigator 1 Incyte Corporation $1,122.30 12/11/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240544856
Principal investigator 1 Incyte Corporation $1,667.70 12/11/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544861
Principal investigator 1 ABBVIE INC. $5,850.00 12/04/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202527840
Principal investigator 1 Incyte Corporation $5,377.60 12/04/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544837
Principal investigator 1 Incyte Corporation $7,340.30 12/04/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544847
Principal investigator 1 Incyte Corporation $1,431.40 12/04/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544952
Principal investigator 1 ABBVIE INC. $964.01 11/26/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202525452
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,133.40 11/26/2025 Non-covered Recipient Entity
Jordan Valley Dermatology
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051020
Principal investigator 1 Incyte Corporation $2,053.80 11/25/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544826
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,000.00 11/24/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252797048
Principal investigator 1 Incyte Corporation $618.75 11/20/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544820
Principal investigator 1 Incyte Corporation $1,000.00 11/20/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544939
Principal investigator 1 Incyte Corporation $2,531.70 11/14/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544805
Principal investigator 1 Incyte Corporation $3,090.60 11/14/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544946
Principal investigator 1 Incyte Corporation $1,506.60 11/07/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544829
Principal investigator 1 ABBVIE INC. $6,735.00 11/05/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202522941
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,551.30 10/27/2025 Non-covered Recipient Entity
Jordan Valley Dermatology
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051018
Principal investigator 1 Incyte Corporation $310.50 10/23/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544793
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,991.60 10/10/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433031
Principal investigator 1 Incyte Corporation $1,026.90 10/09/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544789
Principal investigator 1 Incyte Corporation $10,000.00 10/09/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544933
Principal investigator 1 Incyte Corporation $2,936.70 10/03/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544799
Principal investigator 1 Incyte Corporation $310.50 09/23/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544777
Principal investigator 1 Incyte Corporation $1,377.90 09/23/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544927
Principal investigator 1 Incyte Corporation $2,306.70 09/12/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544773
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $14,000.00 09/11/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252797046
Principal investigator 1 ABBVIE INC. $2,025.00 09/04/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202508460
Principal investigator 1 Incyte Corporation $1,026.90 09/04/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544784
Principal investigator 1 Incyte Corporation $1,110.60 08/26/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544755
Principal investigator 1 Incyte Corporation $4,989.60 08/21/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544769
Principal investigator 1 Incyte Corporation $1,689.30 08/21/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544923
Principal investigator 1 Eli Lilly and Company $7,500.00 08/08/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187885170
Principal investigator 1 Incyte Corporation $621.00 08/07/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544761
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,755.70 08/07/2025 Non-covered Recipient Entity
Jordan Valley Dermatology
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051016
Principal investigator 1 ABBVIE INC. $3,335.00 08/06/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202502528
Principal investigator 1 Incyte Corporation $2,223.00 07/22/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544745
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,991.60 07/18/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433027
Principal investigator 1 Incyte Corporation $1,545.30 07/17/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544915
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $192.00 07/15/2025 Non-covered Recipient Entity
Jordan Valley Dermatology
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051014
Principal investigator 1 Incyte Corporation $2,136.60 07/10/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544740
Principal investigator 1 Incyte Corporation $310.50 07/04/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544750
Principal investigator 1 ABBVIE INC. $3,530.00 07/02/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202495909
Principal investigator 1 Incyte Corporation $3,247.20 06/24/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544702
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $77.00 06/17/2025 Non-covered Recipient Entity
Jordan Valley Dermatology
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051012
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,500.00 06/05/2025 Non-covered Recipient Entity
Jordan Valley Dermatology Center
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235996417
Principal investigator 1 Incyte Corporation $2,136.60 06/05/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544709
Principal investigator 1 ABBVIE INC. $3,530.00 06/03/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202488487
Principal investigator 1 Incyte Corporation $1,026.90 05/28/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544696
Principal investigator 1 Incyte Corporation $5,179.50 05/28/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544909
Principal investigator 1 Incyte Corporation $1,110.60 05/22/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544691
Principal investigator 1 ABBVIE INC. $13,095.00 05/07/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202482497
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,000.00 05/07/2025 Non-covered Recipient Entity
Jordan Valley Dermatology
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051008
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 05/07/2025 Non-covered Recipient Entity
Jordan Valley Dermatology
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051010
Principal investigator 1 Incyte Corporation $1,110.60 04/28/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544673
Principal investigator 1 Incyte Corporation $1,026.90 04/23/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544678
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,234.60 04/17/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433022
Principal investigator 1 Incyte Corporation $1,731.60 04/15/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544664
Principal investigator 1 ABBVIE INC. $13,690.00 04/03/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202470144
Principal investigator 1 Incyte Corporation $3,332.70 04/01/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544684
Principal investigator 1 Incyte Corporation $391.68 03/27/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240544734
Principal investigator 1 Incyte Corporation $1,026.90 03/11/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544654
Principal investigator 1 ABBVIE INC. $3,400.00 03/07/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202461857
Principal investigator 1 Incyte Corporation $2,221.20 03/04/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544658
Principal investigator 1 SANOFI US SERVICES INC. $10,196.01 03/04/2025 Non-covered Recipient Entity
Jordan Valley Dermatology Research Center
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1226083084
Principal investigator 1 Amgen Inc. $132.74 02/25/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246643234
Principal investigator 1 Incyte Corporation $9,613.80 02/25/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544902
Principal investigator 1 ABBVIE INC. $80.46 02/20/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY PLLC
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202453116
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,231.80 02/07/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433019
Principal investigator 1 Amgen Inc. $5,138.11 01/30/2025 Covered Recipient Teaching Hospital
Driscoll Childrens Hospital
A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1246638122
Principal investigator 1 Incyte Corporation $16,390.44 01/23/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240544714
Principal investigator 1 Eli Lilly and Company $115,148.00 01/08/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187885172
Principal investigator 1 Incyte Corporation $2,137.50 01/07/2025 Non-covered Recipient Entity
JORDAN VALLEY DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240544897